Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era

The prognostic value of serum beta-2 microglobulin for diffuse large B-cell lymphoma (DLBCL) is not well known in the rituximab era. A retrospective registry data analysis of 833 patients with de novo DLBCL treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Seo, Seyoung, Hong, Jung Yong, Yoon, Shinkyo, Yoo, Changhoon, Park, Ji Hyun, Lee, Jung Bok, Park, Chan-sik, Huh, Jooryung, Lee, Yoonse, Kim, Kyung Won, Ryu, Jin-Sook, Kim, Seok Jin, Kim, Won Seog, Yoon, Dok Hyun, Suh, Cheolwon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363560/
https://www.ncbi.nlm.nih.gov/pubmed/27764777
http://dx.doi.org/10.18632/oncotarget.12734

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363560/
https://www.ncbi.nlm.nih.gov/pubmed/27764777
http://dx.doi.org/10.18632/oncotarget.12734

Ejemplares similares